HanchorBio and Kaohsiung Medical University Hospital Sign MOU to Strengthen Cancer Clinical Research Collaboration
Combining innovative drug development and clinical expertise to explore future medical research opportunities, with a focus on patient safety and research collaboration
[Taipei, Shanghai, San Francisco | November 5, 2026] – HanchorBio, Inc. (TWSE: 7827), a global clinical-stage biotechnology company developing next-generation immunotherapies for oncology and immune-mediated diseases, today announced the signing of a Memorandum of Understanding (MOU) with Kaohsiung Medical University Hospital (KMUH). The collaboration combines HanchorBio’s expertise in innovative drug development and clinical development with KMUH’s clinical and research expertise in gastrointestinal oncology to explore potential opportunities for future clinical research. Both parties aim to generate additional scientific evidence in cancer research through clinical studies, while maintaining rigorous standards of patient safety, medical ethics, and regulatory compliance.
The MOU represents an important step toward establishing a foundation for further collaboration between HanchorBio and KMUH in clinical research and medical innovation. Through professional exchanges and resource integration, both parties intend to evaluate appropriate directions for research collaboration and strengthen the connection between innovative drug development and clinical needs.
Focusing on Clinical Needs in Cancer and Strengthening Research Collaboration
KMUH brings extensive clinical expertise in the treatment and medical research of gastrointestinal cancers, while HanchorBio focuses on innovative drug development and clinical development in oncology and immune-mediated diseases. By combining their respective expertise in clinical medicine and biotechnology research, both parties aim to explore appropriate models for research collaboration through ongoing dialogue and evaluation, in accordance with Taiwan’s regulatory and medical ethics requirements.
Professor Jaw-Yuan Wang, President of KMUH, noted that the Taiwan government’s “Healthy Taiwan” policy aims to improve public health and strengthen cancer prevention and control efforts, while medical institutions must continue to enhance the quality of clinical care and research. He emphasized that the primary purpose of the MOU is to establish a framework for communication and evaluation of clinical research-related matters between the two parties, with the scope of collaboration focused on exploring potential clinical research opportunities. Should specific research projects be proposed in the future, each will be evaluated objectively and prudently based on its research design and scientific evidence, and will undergo the necessary review and approval procedures in accordance with applicable regulations to ensure research quality, participant safety, and the protection of participants’ rights and interests.
Advances in Innovative Immunotherapy Research: Connecting Science with Clinical Needs
HanchorBio continues to develop innovative immunotherapies through its proprietary FBDB™ multifunctional biologics platform. Its lead investigational candidate is designed to block the CD47–SIRPα immune checkpoint to enhance macrophage-mediated antitumor immune responses and explore the interplay between innate and adaptive immunity. Related preclinical findings have been published in the international scientific journal Journal of Hematology & Oncology, providing an important scientific foundation for further research.
The investigational candidate is currently being evaluated in Phase 1b/2a clinical trials in Taiwan, the United States, and other regions, covering solid tumors including gastric cancer, gastroesophageal junction cancer, and colorectal cancer. Clinical findings remain preliminary, and the safety and efficacy of the investigational therapy have yet to be confirmed in subsequent studies. These findings will inform the evaluation of future clinical development strategies.
Exploring Future Collaboration with Patient Safety and Medical Ethics at the Core
Under the MOU, HanchorBio and KMUH will engage in discussions and evaluations of potential research directions and implementation approaches based on clinical needs. By leveraging their respective expertise and resources, both parties aim to progressively strengthen their collaboration and contribute to the advancement of clinical research and medical science.
“The value of innovative drug development lies not only in continued scientific progress, but also in addressing real-world clinical needs,” said Scott Liu, Ph.D., Chairman and Chief Executive Officer of HanchorBio. “Signing this MOU with KMUH represents an important step in strengthening HanchorBio’s collaboration with medical institutions in Taiwan. We look forward to combining our respective expertise to continue exploring appropriate directions for clinical research collaboration and contributing to the advancement of medical research.”
Connecting Clinical Care with Innovative Drug Development to Strengthen Collaboration
The signing of this MOU establishes a foundation for further engagement and collaboration between HanchorBio and KMUH. Moving forward, both parties will continue exploring opportunities for clinical research collaboration, facilitating professional exchanges between medical institutions and the biotechnology industry, and supporting the advancement of medical research in accordance with applicable regulatory and medical research ethics requirements.
HanchorBio remains committed to innovative drug development and global clinical development. Through continued collaboration with medical institutions and research teams, the Company aims to deepen its understanding of clinical needs, strengthen the connection between scientific research and clinical care, and establish a broader foundation for future medical innovation.
Looking ahead, HanchorBio will continue advancing its global clinical development programs, including planned randomized clinical studies in second-line gastric and gastroesophageal junction cancers and ongoing combination studies across multiple solid tumor types. In parallel, the Company will continue strengthening collaborations with qualified medical institutions and research teams, combining innovative drug development capabilities with clinical expertise to generate additional scientific evidence that may inform future clinical development and medical research.
About HanchorBio
HanchorBio, Inc. (TWSE: 7827) is a global clinical-stage biotechnology company developing next-generation biologics for cancer and immune-mediated diseases through its proprietary FBDB™ platform. Powered by multifunctional protein-engineering technology, its pipeline includes HCB101, HCB301, and HCB303. All three candidates are investigational products that have not received marketing approval in Taiwan or any other country.
With operations across Taipei, the San Francisco Bay Area, and Shanghai, HanchorBio is committed to reimagining immunotherapy and creating new treatment possibilities for patients worldwide. For more information, please visit: https://www.HanchorBio.com.
Important Notice
This MOU does not constitute approval of or a commitment to any specific clinical trial or treatment. Any clinical research involving investigational products conducted by HanchorBio and KMUH must receive prior approval from the relevant regulatory authorities and Institutional Review Boards (IRBs). The safety and efficacy of HanchorBio’s investigational products have not been established. Patients seeking treatment should consult their treating physicians.
Forward-Looking Statements
This press release contains forward-looking statements, including statements regarding potential future collaboration between HanchorBio and KMUH and plans for clinical research cooperation. Any subsequent collaboration or research activities will be subject to applicable laws and regulations, medical ethics requirements, and relevant institutional procedures. Actual activities and timelines may be adjusted due to regulatory, clinical, operational, and other factors.
HanchorBio undertakes no obligation to update forward-looking statements except as required by applicable law. HanchorBio is solely responsible for statements in this press release concerning its products, operations, and research and development plans.
Investor & Media Contact:
Email: [email protected]
HanchorBio Business Development Contact:
Email: [email protected]
漢康生技攜手高醫簽署合作備忘錄 深化癌症臨床研究合作
結合創新藥物研發與臨床醫療專業，聚焦病人安全及研究合作，探索未來醫療創新研究合作機會
【台北、上海、舊金山，2026 年 11 月 5 日】－全球臨床階段生技公司漢康生技（TWSE：7827）今日宣布，與高雄醫學大學附設中和紀念醫院（以下簡稱「高醫」）正式簽署合作備忘錄（MOU），雙方將結合漢康生技在創新藥物研發及臨床開發方面的經驗，以及高醫在消化系癌症臨床醫療與研究領域的專業，探索未來臨床研究的可能性，期望在兼顧病人安全、醫療倫理及法規要求的前提下，透過臨床研究，累積癌症相關之醫學研究證據。
此次合作象徵漢康生技與高醫在臨床研究及醫療創新領域建立進一步合作的基礎。雙方期望透過專業交流與資源整合，評估適當的研究合作方向，促進創新藥物研發與臨床醫療需求之間的連結。
聚焦癌症臨床需求 深化研究合作
高醫長期深耕消化系癌症的臨床診療與醫學研究，累積豐富的臨床專業經驗；漢康生技則專注於癌症及免疫介導疾病領域的創新藥物研發與臨床開發。此次合作將結合雙方在臨床醫療與生技研發領域的專業，透過持續交流與合作評估，探索符合台灣法規及醫療倫理要求的研究合作模式。
高醫院長王照元教授表示，政府推動「健康台灣」政策，致力提升國人健康並強化癌症防治成效，醫療機構亦應持續精進臨床照護與研究品質。此次簽署合作備忘錄，主要在建立雙方就臨床研究相關議題交流與評估的機制，合作範圍以臨床研究合作的可能性為主，未來若有具體研究計畫，也將依個別研究內容及科學證據，秉持客觀、審慎的原則進行評估，並依相關法規完成必要的審查與核准程序，以確保研究品質、受試者安全及權益保障。
創新免疫療法研究進展 串聯科學與臨床需求
漢康生技透過自主研發的 FBDB™ 多功能生物藥平台，持續開發創新免疫療法。旗下主力候選藥物主要透過阻斷 CD47–SIRPα 免疫檢查點，旨在促進巨噬細胞介導的抗腫瘤免疫反應，並探索先天性免疫與適應性免疫之間的交互作用。相關臨床前研究成果已發表於國際學術期刊《Journal of Hematology & Oncology》，提供後續研究的重要科學基礎。
目前相關候選藥物正於台灣、美國等地進行第一 b/二 a 期臨床試驗，研究涵蓋胃癌、胃食道交界部癌及大腸直腸癌等實體腫瘤。現階段臨床研究數據仍屬初步，藥物安全性及療效尚待後續試驗進一步確認，相關研究結果將作為後續臨床開發策略的評估依據。
以病人安全與醫療倫理為核心 探索未來合作方向
根據此次簽署的合作備忘錄，雙方將以臨床需求為出發點，就未來可能的研究合作方向及執行方式進行交流與評估，結合各自的專業與資源，逐步深化合作，共同促進臨床研究與醫學發展。
漢康生技董事長暨執行長劉世高博士表示：「創新藥物研發的價值，不僅在於科學研究的持續進展，更在於如何回應臨床醫療的實際需求。此次與高醫簽署合作備忘錄，是漢康生技深化台灣醫療機構合作的重要一步。我們期待結合雙方的專業經驗，持續探索適當的臨床研究合作方向，促進相關醫學研究發展。」
串聯臨床醫療與創新研發 持續深化合作
此次合作備忘錄的簽署，為漢康生技與高醫建立進一步交流與合作的基礎。未來，雙方將持續探索臨床研究合作機會，促進醫療機構與生技產業之間的專業交流，並在符合相關法規與醫學研究倫理要求的前提下，共同推動醫學研究發展。
漢康生技將持續投入創新藥物研發與全球臨床開發，並透過與醫療機構及研究團隊的合作，深化對臨床需求的理解，促進科學研發與臨床醫療的連結，為未來醫療創新奠定更完整的合作基礎。
展望未來，漢康生技將持續推進全球臨床開發計畫，包括規劃中的二線胃癌及胃食道交界部癌隨機分組臨床研究，以及多項實體腫瘤聯合治療試驗。同時，公司將持續深化與專業醫療機構及研究團隊的合作，結合創新藥物研發與臨床專業，進一步累積研究證據，作為後續臨床開發與醫學研究的參考。
關於漢康生技
漢康生技（TWSE：7827）是一家全球臨床階段生技公司，透過自主開發的 FBDB™ 平台，致力於研發癌症及免疫介導疾病的下一代生物藥。憑藉多功能蛋白質工程技術，公司建立了包括 HCB101、HCB301 及 HCB303 在內的創新產品管線，上述產品均為研發中之試驗用藥物，尚未於我國或其他國家取得上市許可。漢康生技於台北、美國舊金山灣區及上海設有營運據點，致力於重新定義免疫治療，為全球病人開創新的治療可能性。
重要聲明
本合作備忘錄不構成任何特定臨床試驗或治療之核准或承諾。漢康與高醫執行任何涉及試驗用藥物之臨床研究，均須事先經主管機關及人體試驗審查委員會核准。漢康生技產品之安全性及療效尚未確立。民眾如有治療需求，請與主治醫師討論。
前瞻性聲明
本新聞稿包含前瞻性聲明，包括有關漢康生技與高醫未來合作方向及臨床研究合作計畫等敘述。任何後續合作或研究活動均須符合適用法規、醫療倫理及相關機構程序，實際執行內容與進度可能因法規、臨床、營運及其他因素而有所調整。除適用法律另有規定外，漢康生技不承擔更新前瞻性聲明的義務。本新聞稿中有關漢康生技產品、營運及研發規劃之敘述，由漢康生技自行負責。